Empagliflozin

Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination

Asian Diabetes Outcomes Prevention Trial

Randomised Evaluation of COVID-19 Therapy

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients

Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Empagliflozin in Patients With Cirrhosis and Ascites

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Safety and Efficacy of Empagliflozin in Hemodialysis

Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease

SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

SGLTi, Hepatic Glucose Production and Ketogenesis

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

Empagliflozin Treatment in Kidney Transplant Recipients

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes

Cardiology Research Dubrava Prospective Registry

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Polypill for Prevention of Cardiomyopathy

SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease

Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

Canagliflozin in Advanced Renal Disease With MRI Endpoints

The STOP-MED CTRCD Trial

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

Ketones, SGLT2, HFrEF

Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease

Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age

Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

Metabolic Response to the Initiation of Heart Failure Therapy

Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)

Mechanism of SGLT2 Inhibition in the Kidney

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

Prevention of Progression of Prediabetes, Obesity and CV Risk

Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients

Empagliflozin Reversal of Arterial StiffnEss in Aging

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

STunning in Acute Myocardial Infarction - BAS

Feasibility Trial for a Right Ventricular Failure Platform Trial

DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

Randomized Trial of SGLT2i in Heart Transplant Recipients

A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)

A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record

A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II

EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Simplification of Oral Sodium Loading Test in the Diagnosis of Primary Aldosteronism: 2-day Replacing 3-day Method

CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

Improving Coronary Vascular Health in Women

Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema

The EMPA-FIT Study

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial

Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

The Use of Advanced Imaging in HFpEF

Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study

RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity

Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets

Dapagliflozin for Cardio-renal Protection After ICU Discharge

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

SGLT2i, Hepatic Glucose Production, and SNS

SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

SGLT2i, Pioglitazone, and Ketone Production in T2D

SGLT2i in Kidney Stones

SGLT2i, Pioglitazone, and Ketone Production in T1D

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction

Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications

Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial

SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients

Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors

Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

SGLT2 Inhibitors in Geographic Atrophy

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

SGLT2i Therapy in Islet Transplantation (SIT)

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

Dapagliflozin in Depression

Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

Effect of Empagliflozin on Inflammation

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Dapagliflozin in Active Lupus Nephritis

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study

Add-on Diuretics in Acute Decompensated Heart Failure

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

Vericiguat and Reverse Remodeling Indices in Heart Failure

Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)

Glycemic Variability of Combination Therapies in T2DM

Transformative Research in Diabetic Nephropathy 2.0

The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.

The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.

Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure

HFrEF Polypill in Sri Lanka RCT

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting

SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"

the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

The Efficacy of Empagliflozin on Kidney Functions in Lupus Nephritis Population

Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer

Mitral Valve Edge-to-Edge Repair in Patients With Exercise-Induced Severe Mitral Regurgitation

The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus

Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome

Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF

Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects

Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes

DDI Between BI Empagliflozin (10773) and Verapamil

Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers

Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin

Drug Interaction Study of Digoxin and BI 10773

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus

Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon

Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.

A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects

Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers

Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers

BI 10773 Administered as Oral Solution to Healthy Male Volunteers

A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers

Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients

Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Pharmacogenetics of SGLT2 Inhibitors

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor

Effect of Dapagliflozine on Systemic and Renal Endothelial Function

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis

Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2

SGLT2 Inhibition and Left Ventricular Mass

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

Empa/Lina FDC Food Effect Study (Japan)

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes

Genetics of Response to Canagliflozin

A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

Cardiovascular Effects of Empagliflozine

Treatment of Diabetes in Patients With Systolic Heart Failure

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes

A Real World Experience of Dapagliflozin in Type 2 Diabetes

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.

Empagliflozin vs Metformin in PCOS

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Characteristics of Empagliflozin Initiators

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Pharmacokinetic Evaluation of Empagliflozin

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

EMPRA (EMPagliflozin and RAs in Kidney Disease)

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Empagliflozin and Renal Oxygenation in Healthy Volunteers

Empagliflozin in Post-Transplantation Diabetes Mellitus

Impact of Empaglifozine on Cardiac Ectopic Fat

Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure

Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

The Effect of Empagliflozin on Glucose Metabolism, Weight, Blood Pressure and Cardiac Function (NT-proBNP) Should be Investigated

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Empagliflozin in Renal Transplant Recipients

PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria

Empaglifozin in Early Diabetic Kidney Disease

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Treatment of IgA Nephropathy According to Renal Lesions

Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Empagliflozin and Hepatic Glucose Metabolism

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction

Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure

Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study

Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes

SGLT2 Inhibition in Combination With Diuretics in Heart Failure

Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes

Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Empagliflozin and Sympathetic Nerve Traffic

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

SGLT2i and Incretin and CRTd.

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Comparative Effectiveness of Empagliflozin in the US

SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease

The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

Performance Under SGLT-2-Inhibitors in Humans

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES

Empagliflozin Effect on Glucose Toxicity

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Empa PASS on Urinary Tract Malignancies

Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

EMPA Acute Heart Failure

Effect of Dapagliflozin on IAH in T1DM

Study to Develop a Kinetic Model for FDG and Me4FDG in Kidneys of Type 2 Diabetic Patients

Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1

Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin

The Effects of Empagliflozin on Arterial Wall Characteristics

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

Efficacy and Safety of Empagliflozin in NODAT

Regulatory Request NIS in Korea

Antidiabetic Drugs for Steatotic Liver Disease

Dapagliflozin Effects on Hypoglycemia

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

Cardiac Autonomic Dysfunction in Diabetics Patients With Syncope

Dapagliflozin Efficacy and Action in NASH

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Prognostic Predictors of Response to Hypoglycemic Therapy

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Approaches To Therapy Escalation In T2D

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial

Effect of Empagliflozin on Body Composition and Ketones

Dapagliflozin Plus Pioglitazone in T1DM

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

Triple Therapy in T1DM

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Effectiveness of Dapagliflozin for Weight Loss

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting

SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes

Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Effect of Empagliflozin on Ventricular Repolarization.

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Surgical or Medical Treatment

Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

SGLT2 Inhibitors in Glomerular Hyperfiltration

Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease

Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

The Effects of SGLTi on Diabetic Cardiomyopathy

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

Short Term Effect of Empagliflozin in Hypertension

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Dapagliflozin Efficacy and Action in PCOS

Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Renohemodynamic Effects of Combined empagliflOzin and LosARtan

Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy

REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

Pharmacological Reduction of Right Ventricular Enlargement

Dapagliflozin in Respiratory Failure in Patients With COVID-19

Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.

Oral Anti Diabetic Agents in the Hospital

Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia